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Abstract. Roughly 40% of all patients with insulin-depen- 
dent diabetes mellitus (IDDM) develop diabetic 
nephropathy with proteinuria, hypertension and a de- 
crease in glomerular filtration rate 10 to 20 years after the 
onset of the disease, and 5 years later most patients uffer 
from end-stage r nal disease. Microalbuminuria, defined 
as an urinary albumin excretion rate (UAER) between 30 
and 300 mg/day, strongly predicts the development of
nephropathy in IDDM. Nearly all patients with IDDM, 
a decreasing lomerular filtration rate and a UAER 
> 300 mg/day have coexisting hypertensive disease addi- 
tionally worsening renal function. We review the results 
of recent long-term studies of the current therapeutic 
management in diabetic patients by means of better 
blood pressure control, low-protein diet and near-normal 
blood glucose control in the early microalbuminuric 
phase as well as in the later phases of the disease charac- 
terized by diabetic nephropathy with a UAER > 300 
mg/day. Since the large majority of studies have been 
performed on IDDM, our conclusions with regard to 
therapy are only valid in this subgroup of diabetic pa- 
tients. 
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Introduction 
Diabetic nephropathy, characterized byproteinuria, hy- 
pertension and a decrease in glomerular filtration rate 
(GFR), occurs in approximately 40% of insulin-depen- 
dent diabetes mellitus (IDDM) patients 10-20 years after 
the onset of IDDM [1, 2]. Microalbuminuria strongly 
predicts the development of diabetic nephropathy [3, 
4, 5]. Very often patients with IDDM, a decreasing GFR 
and a urinary albumin excretion rate (UAER) > 300 mg/ 
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day have coexisting hypertensive disease additionally 
worsening renal function [6]. Diabetic nephropathy is 
one of the leading causes of end-stage renal disease [7]. 
Therefore therapeutic regimens to delay or even prevent 
the development of end-stage renal disease are of great 
importance. We discuss three different herapeutic ap- 
proaches to diabetic nephropathy in the microalbumin- 
uric and macroalbuminuric phases of the disease. First, 
the influence of blood glucose levels on the progression of
the disease is considered. Second, the effects of low- 
protein diets on GFR and micro- and macroalbuminuria 
are evaluated. Finally, the role of antihypertensive th ra- 
py in normotensive or hypertensive patients with either 
micro- or macroalbuminuria is discussed. 
Blood glucose control 
Blood glucose control in microaIbuminuria 
and diabetes meIlitus 
Recently a number of long-term studies investigating 
whether the development of diabetic nephropathy may 
be prevented or slowed by strict glycaemic control, mea- 
sured by HbA1 levels, have been published. The Kroc 
Collaborative Study Group demonstrated a ecrease in 
UAE in patients with a HbA1 c level of 8.1% over a peri- 
od of 8 months. Feldt-Rasmussen t al. studied patients 
with a HbA1 c level of 7.2% over 2 years and also noted 
a decrease inalbumin excretion. In both studies the group 
of patients with HbA1 c levels of 8.1% or 7.2%, respec- 
tively, were treated with continuous subcutaneous in ulin 
infusion (CSII). None of the patients in the control group 
receiving conventional insulin treatment (CIT) showed a
significant or sustained improvement in the degree of 
metabolic ontrol [8, 9, 10]. The Kroc Collaborative 
Study Group found a decrease in UAER in microalbu- 
minuric patients on CSII with HbA1c levels of 8.1% 
[8, 9]. In contrast, Feldt-Rasmussen et al. did not observe 
a decrease in UAER in subjects on CSII, and indeed the 
rate was unchanged after 2 years of treatment (170 vs 
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160 mg/min). On the other hand, microalbuminuric pa- 
tients on CIT experienced no change in HbAIr and a 
significant rise in UAER (160 vs 360 mg/min) [10]. Good 
blood glucose control with HbAI~ levels of 8.1% or 7.2% 
was achieved with CSII (Table 1) [8, 9, 10]. Reichard 
et al. treated 44 patients with intensified insulin treat- 
ment (IIT) for 3 years. The measured HbAI~ levels were 
7.4% compared with 9.0% in the control patients who 
received regular insulin treatment. The improved blood 
glucose control of the 44 patients being treated with IIT 
delayed the development of diabetic nephropathy com- 
pared with the control patients receiving regular treat- 
ment [11]. In the Steno 1 and Steno 2 studies [12] a total 
of 51 patients with IDDM and microalbuminuric were 
followed for 8 and 5 years. In the conventional treatment 
group an increase in UAER, a decline in GFR and a rise 
in blood pressure were found only in patients with high 
microalbuminuria (100-300rag/day), whereas in the 
same subgroup of patients treatment with CSII resulted 
in a stable UAER and GFR. Analysing the 19 patients 
with a UAER of 100-300 mg/day, 2 out of 9 in the CSII 
group progressed to diabetic nephropathy, compared 
with 10 out of 10 patients in the regular treatment group. 
Only 1 patient out of 32 with microalbuminuria n the 
range of 30-99 mg/day developed diabetic nephropathy. 
Intensive blood glucose control in the Diabetes Control 
and Complications Trial (DCCT) was associated with a 
39% reduction in the occurrence of microalbuminuria 
(> 40 rag/day) and a 54% reduction in the occurrence of 
diabetic nephropathy (> 300 mg/day). In this study 1441 
IDDM patients were followed for a median of 6.5 years 
after random allocation to intensive therapy (external 
insulin pump or > 3 daily insulin injections) or to con- 
ventional therapy (_< 2 daily insulin injections) [13]. 
Blood glucose control with near-normal UAER 
in diabetes mellitus 
In the 7-year Oslo study [14], 8 out of 10 patients with 
IDDM and HbA1 levels of 8.5% showed a decrease in 
UAER, while 4 out of 14 patients with HbA1 levels 
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greater than 10% developed significant increases in 
UAER to > 200 rag/day. Blood glucose control was 
achieved by CSII in 10 patients, by IIT in 33 patients and 
by CIT in 2 patients. All patients participating in the Oslo 
study had a mean UAER in the upper normal range 
during the 2 months prior to enrolment in the study 
(Table 1). Thus, near-normoglycaemic blood glucose lev- 
els with HbA1 levels below 8% delay the onset of diabetic 
nephropathy in patients with microalbuminuria nd 
UAER in the upper normal range. It remains unproved 
whether good glycemic ontrol prevents worsening of re- 
nal function in manifest diabetic nephropathy. 
Protein restriction 
Effect of protein restriction in diabetic nephropathy 
Low-protein diets improve the haemodynamic situation 
in the glomerulus and reduce proteinuria in rats with 
streptozocin (STZ)-induced iabetes. The degree of his- 
tological change in diabetic nephropathy is also im- 
proved by a low-protein diet [15, 16]. Walker et al. [17] 
and Zeller et al. [18] examined the effects of a low-protein 
diet (0.6-0.7 g protein/kgper day) in 19 and 20 patients, 
respectively, with diabetic nephropathy. The study by 
Walker et al. had a case-control design. In the study by 
Zeller et al., 15 patients received acontrol diet containing 
at least 1 g protein/kg per day. The follow-up periods 
were 33 and 37 months, respectively, for the two studies. 
The patients with a restricted protein intake had a de- 
crease in proteinuria and a reduced decline in GFR 
(Fig. 1). In another study Brouhard and LaGrone also 
demonstrated a beneficial effect of a reduced protein in- 
take on GFR and on albuminuria [19]. Evanoffet al. [20] 
observed eight patients with IDDM, proteinuria (protein 
excretion >0.5 g/day) and renal insufficiency for 12 
months before and 12 months after the introduction of 
dietary protein restriction to 40 g high biological value 
protein/day. The creatinine clearance before starting the 
protein-restricted diet (55 + 27) ml/min was not signifi- 
cantly different from that after 12 months of the diet (56 
_+ 25 ml/min). The mean daily urinary protein excretion 
Table 1. Blood glucose control and its effect on UAER and GFR in diabetes mellitus 
Kroc Collaborative Feldt-Rasmussen Steno 1 and 2 [12] Oslo study [14] 
Insulin regimen CIT CSII CIT CSII CIT CSII CIT, CSII or IIT 
Number of patients 10 10 18 18 10 9 45 
Follow-up 8 months 24 months 5-8 years 7 years 
HbA/c (%) HbA1 HbA1 HbAI 
End of study 10.3 8.0 8.6 7.2 9.4 7.7 <9.0 9.1-10 >10 
UAER (mg/day) 
Beginning of study 70.4 70.4 88.7 95.2 181 t63 20 17 26 
End of study nsd 2.3* 100 78** 713 167"* 25 25 91" 
GFR (ml/min) 
Beginning of study - - 116 109 110 113 115 114 118 
End of study - - 114 99 87 100 108 107 114 
CIT, Conventional insulin treatment; CSII, continuous ubcutaneous insulin infusion; ITT, intensified insulin treatment; nsd, no significant 
decline 
* Significant difference between beginning and end of study (P _< 0.02) 
** Significant difference between CIT and CSII at end of study (P < 0.002) 
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fell from 2.11 _+ 1.36 g/day before dietary protein restric- 
tion was started to 0.14 _+ 0.16 g/day after 12 months of 
the diet. In a later study [21], Evanoff et al. followed 11 
IDDM patients uffering from proteinuria (> 0.5 g/day) 
and renal insufficiency on a diet containing 0.6 g/kg per 
day high biological value protein for 2 years. In a similar 
manner to the earlier 12-month study, creatinine clear- 
ances at 12 and 24 months of protein restriction were not 
significantly different from those obtained at the begin- 
ning of the low-protein diet. Urinary protein excretion 
again decreased after the initial 12 months to 0.57 + 0.40 
g/day compared with 2.27_+ 0.49 g/day at the beginning 
of the study. However, after 24 months of the low-protein 
diet urinary protein excretion increased to 1.43 _ 0.63 g/ 
day. According to the authors, one reason for this phe- 
nomenon might have been non-compliance with the di- 
etary regimen, expressed as higher urea nitrogen concen- 
trations in urine samples. 
Effect of protein restriction on GFR and microalbuminuria 
In a crossover study lasting only 3 weeks, Cohen et al. 
observed a decrease in UAER to 22 mg/day in eight nor- 
I ]=  15 
146 ~ ** end of study decline in n = 1 9 
GFR (ml/mia per year] [~  rl = 20 
lOOiit ~ :. ,~** f1'0 
*k 
begJmlmg of study 
Proteinuria (~day) 
Walker et al. [I7] Zeller et al. [18] 
Fig. 1. Decline in UAER and diminished loss of GFR with low- 
protein diet (0.6-0.7 g/kg per day). Open bar, control group;filled 
bar, treatment group 
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motensive patients with IDDM and microalbuminuria 
who received a low-protein diet of 38-57 g protein/day. 
A protein intake of 55-117 g/day resulted in UAER of 
33 rag/day [22]. The results of this study imply that a 
low-protein diet causes a reduction in UAER even in the 
microalbuminuric phase of the disease. Long-term stud- 
ies with a larger number of patients are required to deter- 
mine the stage of disease (microalbuminuria versus 
nephropathy) at which protein restriction should be 
started. 
Role of antihypertensive therapy 
Normotension and microalbuminuria n diabetes mellitus 
In a randomized, placebo-controlled, double-blind study 
of 20 patients, of whom 10 suffered from NIDDM, mi- 
croalbuminuria and normotension and the other 10 from 
IDDM, microalbuminuria nd normotension, Marre 
et al. demonstrated that the ACE inhibitor enalapril 
20 rag/day induced a significant decrease in UAER dur- 
ing the first 6 months of treatment. None of the diabetics 
in the treatment group developed iabetic nephropathy, 
whereas three patients in the placebo group progressed to 
diabetic nephropathy during the complete follow-up of 
1 year [23, 24]. However, the mean arterial pressure was 
reduced by enalapril administration (Table 2). It is not 
clear whether the decrease in mean arterial pressure or 
the vasodilating effect of the ACE inhibitor at the vas 
efferens was responsible for the noted decrease in mi- 
croalbuminuria [23, 24]. The Melbourne Study Group 
followed 43 diabetic patients for 1 year, of whom 30 were 
normotensive and 13 hypertensive, and 19 suffered from 
IDDM and 24 from NIDDM [25]. In the subgroup of 
patients with IDDM or NIDDM, microalbuminuria and 
normotension there was no significant change in UAER 
under treatment with either perindopril or nifedipine. 
None of these patients progressed to diabetic nephropa- 
thy. In the 13 hypertensive subjects also suffering from 
Table 2. Normotension and microalbuminuria in diabetes mellitus 
Melbourne Study Group [25] 
Perindopril Nifedipine 
(2-8 mg/day) (20-80 mg/day) 
Mathiesen et al. [28] Marre et al. [23, 24] 
Captopril Control Enalapril Control 
(25-100mg/day) (20mg/day) 
Number of patients 30 30 
Follow-up 12 months 
Mean RR (mmHg) 
Beginning of study 99 99 
End of study 93 93 
UAER (rag/day) 
Beginning of study 49 45 
End of study 36 48 
GFR (mg/min) 
Beginning of study - 
End of study 
21 23 i0 10 
4 years 12months 
103 101 90 97 
98 100 86 102 
82 105 - - 
57 166" - - 
126 129 131 129" 
120 127 124 109'* 
* Significant difference between two treatment groups at end of study (P < 0.05) 
** Significant difference between beginning and end of study (P < 0.05) 
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IDDM or NIDDM and microalbuminuria, both treat- 
ments reduced UAER significantly (Table 2). Cook et al. 
found a significant decrease inUAER during 3 months of 
ACE inhibitor therapy with captopril n 12 normotensive 
adolescents [26]. Another short-term study lasting 6 
weeks [27] showed a40% decrease inUAER during cap- 
topril treatment compared with a 40% increase during 
nifidepine treatment and no change in UAER in the 
placebo group. The study population comprised microal- 
buminuric patients with IDDM randomly assigned to 
one of the two treatment groups or to the placebo group. 
In a 4-year prospective randomized, controlled study of 
44 normotensive patients with microalbuminuria and ID- 
DM [28], captopril 25-100 rag/day with the addition of 
bendrofluazide 2.5 mg/day after 30 months resulted in a 
decrease in UAER. During this long-term study none of 
the patients in the treatment group progressed todiabetic 
nephropathy, whereas seven patients in the placebo 
group developed iabetic nephropathy with a UAER of 
> 300 rag/day (Table 2). The above-mentioned results 
suggest a positive ffect of ACE inhibition on renal func- 
tion in patients with microalbuminuria and normoten- 
sion. 
Hypertension and mieroalbuminuria in diabetes mellitus 
Patients with diabetes mellitus and microalbuminuria of-
ten suffer from high blood pressure in the further course 
of their disease. Christensen and Mogensen observed a
correlation between the duration of the disease and the 
degree of microalbuminuria, as well as between the eleva- 
tion of diastolic blood pressure and the worsening of 
microalbuminuria [29]. Gambardella et al. treated ten 
patients with NIDDM, hypertension a d microalbumin- 
uria with indapamide 2.5 mg/day for 2 years [30]. Mi- 
croalbuminuria significantly decreased. Two studies have 
compared the effects of an ACE inhibitor and a calcium 
antagonist inhypertensive patients with diabetes mellitus 
and microalbuminuria: 2-8 rag/day perindopril vs 20- 
80 rag/day nifedipine in 13 IDDM and NIDDM patients 
for 12 months [25]; 10-20 rag/day enalapril vs 60-120 
rag/day nicardipine in seven IDDM patients for 4 weeks 
[31]. No significant differences in terms of lowering of 
blood pressure, decrease in microalbuminuria and GFR 
could be shown between the two types of agents [25, 31]. 
In contrast, Pedersen et al. observed a further decline in 
UAER after adding an ACE inhibitor to the antihyper- 
tensive regimen in ten patients with IDDM [32]. Anti- 
hypertensive treatment is valuable in patients with micro- 
albuminuria nd hypertension. In animal studies ACE 
inhibitors have been shown to be superior to other anti- 
hypertensive agents, but as far as we know, long-term 
studies proving superiority of ACE inhibitors over con- 
ventional antihypertensive therapy in humans are lack- 
ing, although as stated above short-term studies demon- 
strate that the addition of an ACE inhibitor to antihyper- 
tensive therapy has a favourable ffect on UAER. 
Normotension and diabetic nephropathy 
Parring et al. [33] found that 15 normotensive IDDM 
patients with nephropathy treated with an ACE inhibitor 
(captopril 25-100 rag/day) for 12 months howed a de- 
crease in mean arterial pressure of 3 mm Hg, in UAER of 
11% and in GFR of 3 ml/min per 1.73 m 2, while the 17 
untreated control patients howed an increase in mean 
arterial pressure of 6 mmHg, an increase in UAER of 
55% and a decrease in GFR of 6 ml/min per 1.73 m 2. 
Although the rate of decline in GFR was not statistically 
significant in this study, the results uggest that treatment 
of patients with still-normal blood pressure and diabetic- 
nephropathy with an ACE inhibitor might reduce the rate 
of or prevent he decline in GFR. 
Hypertension and diabetic nephropathy 
Diabetic patients with nephropathy ave a 50-70% risk 
of developing hypertension, often resulting in a further 
decline in renal function [1]. In the first long-term study 
of a small group of patients with IDDM, proteinuria and 
high blood pressure treated with propanolol and later 
with metoprolol (100-200 mg/day), adiminished loss of 
GFR and a decrease in proteinuria was found in treated 
patients. Three and four, respectively, of the six patients 
were additionally treated with 40 mg/day frusemide and 
100-200 mg/day hydralazine [34]. Good blood pressure 
control achieved with metoprolol, hydralazine and 
frusemide was shown to slow the decline in GFR and 
reduce proteinuria n 11 patients with IDDM, nephropa- 
thy and high blood pressure. This study lasted for 6 years 
[35], and a follow-up to a total of 9.7 years confirmed the 
results in the same 11 patients [36]. The rate of the decline 
in GFR decreased from 10.7 ml/min per year before 
treatment to2.5 ml/min per year during antihypertensive 
therapy. UAER fell from 1.5 g/day to 0.8 g/day [36]. In 
another study, Parring et al. treated 18 hypertensive pa- 
tients with nephropathy with the ACE inhibitor captopril 
and a diuretic frusemide or bendrofluazide. During the 
2.5 years of follow-up UAER decreased and a reduced 
decline in GFR was noted (Fig. 2) [37]. Bj6rk et al. used 
an antihypertensive th rapy combining an ACE inhibitor 
(captopril), a diuretic, a beta-blocker and a calcium an- 
tagonist [38]. Mean arterial blood pressure was lowered 
by 5 mmHg and the decline in renal function was slowed 
in all 14 patients (Fig. 2). Bjtrk et al. thus confirmed the 
beneficial impact of ACE inhibition on UAER and GFR. 
In a 2-year follow-up, 22 of 40 IDDM patients with dia- 
betic nephropathy were treated with 5- 20 mg/day enala- 
pril and the other 18 patients received up to 200 mg/day 
metoprolol [39]. A diuretic was added to the treatment of
both groups. The rate of decline in GFR was 2.0 ml/min 
per year in the enalapril group and 5.6 ml/min per year, 
a surprisingly high value, in the metoprolol group. 
UAER was 60% lower in the enalapril group. The supine 
diastolic blood pressure was 6mmHg lower in the 
enalapril group, whereas the standing mean arterial pres- 
sure did not differ significantly between the two treat- 
ment groups. In the group treated with enalapril one 
patient had a rise in serum creatinine and was withdrawn 
from the study. However, asuperior effect on GFR of an 
ACE inhibitor compared with a beta-blocking agent 
could not be confirmed in a study by Grtnhagen-Riska 
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Proteinuria (g/day) 
Decrease in GFR 
(ml/min per year) 
Captopril 
Frusemide 
Metoprolol 
(n= 15) 
3-  
1 i2 
Bj6rk et al, [38] 
Control Captopril 
Group Frusem idc 
(n = 13) (n = 18) 
Parving et al. [37] 
Fig. 2; Effects of antihypertensive treatment on proteinuria and 
GFR in patients with diabetic nephropathy. Open bar, before ther- 
apy; filled bar, after therapy 
et al. [40]. In a recent study by Lewis et al., 409 IDDM 
patients were followed up for a median of 3 years in a 
randomized controlled trial. 207 patients (I 55 hyperten- 
sive) received 3 9 25 mg/day of captopril and 202 patients 
(153 hypertensive) received placebo. Doubling of serum 
creatinine and the combined endpoints of death, dialysis 
and transplantation were significantly higher in the 
placebo group. However blood pressure control was bet- 
ter, GFR as baseline higher and protein excretion lower 
in the captopril group [41]. Therapy to normalize blood 
pressure slows the progression of renal disease in mani- 
fest diabetic nephropathy, but study results o far have 
not demonstrated a clear superiority of any one class of 
antihypertensive agents (e.g. ACE inhibitors). 
Future trends and perspectives 
in treating diabetic nephropathy 
In animal models thromboxane (TX) A2 seems to be of 
relevance in the pathogenesis of diabetic nephropathy. In 
a controlled study the effects of the dietary administra- 
tion of the TX synthetase inhibitor OKY-046 on urinary 
protein excretion and serum BUN were evaluated in 20 
STZ-induced iabetic rats [42]. The treated group devel- 
oped a urinary protein excretion of 64.1 rag/day com- 
pared with 85.6 mg/day in the control group. The treated 
rats also showed a reduced thickening of the glomerular 
basement membrane, lower serum glucose levels and nor- 
malization of enhanced platelet aggregation, but no sig- 
nificant differences in the serum BUN levels of the treat- 
ed and control groups were found. Unfortunately the 
GFR was not studied. No side effects of OKY-046 have 
been reported. It might herefore be a promising therapy 
in humans as well, but further evaluation isclearly need- 
ed. 
In experimental diabetes using STZ diabetic rats, 
the administration of indomethacin an inhibitor of 
prostaglandin synthesis, leads to an increase in the affer- 
ent arteriolar hydraulic resistance and a moderate in- 
crease in the efferent resistance causing areduction i  the 
hydraulic pressure in the glomerular capillaries [43]. In a 
small randomized ouble-blind trial the effects of 150 
mg/day indomethacin for 3 days were studied in 8 pa- 
tients with IDDM and microalbuminuria, who were 
compared with a placebo group of 9 normoalbuminuric 
IDDM patients and 11 healthy controls [44]. Indo- 
methacin caused a significant reduction in UAER (from 
207 to 87 rag/day) and in prostaglandin E2 urinary ex- 
cretion (from 317 to 103 pg/ml), which was elevated 
compared with two control groups not suffering from 
microalbuminuria. GFR remained stable. In a more re- 
cent study the beneficial effect of indomethacin o exerci- 
se-induced UAER in IDDM with microalbuminuria w s 
confirmed [45]. Of the 14 patients with IDDM studied, 9
suffered from microalbuminuria at rest and 5 were nor- 
moalbuminuric. The patients were treated in a random- 
ized cross-over design with a single oral dose of indo- 
methacin, metoprolol or placebo shortly before exercis- 
ing. The rise in UAER in the microalbuminuric patients 
receiving indomethacin was lower than in those receiving 
placebo or metoprolol (7, 29 and 18 Bg/min). Although 
the results of animal studies and short-term evaluations 
in small groups of patients are promising, the long-term 
influence of prostaglandin synthesis nhibitors on diabet- 
ic nephropathy is not yet known. 
Some investigators have suggested the polyol-sorbitol 
pathway to be of major importance inthe development of 
diabetic nephropathy. Oates et al. demonstrated a ose- 
dependent reduction in UAER in STZ-induced iabetic 
rats being treated with zopolrestat, an aldose-reductase 
inhibitor [46]. With a dose of 100 mg/kg the elevated 
UAER was reduced by 77%. In a short-term double- 
blind, cross-over study aldose reductase inhibition with 
600 mg/day polanrestat given for 3 months to 28 micro- 
albuminuric IDDM patients decreased UAER signifi- 
cantly compared with placebo (37 mg/day decrease vs 
16.5 mg/day increase) [47]. 
Although, as mentioned above, ACE inhibitors o far 
have not been proven to be superior to other antihyper- 
tensive agents in delaying the decline in renal function in 
patients with microalbuminuria in long-term studies, the 
treatment of diabetic uninephrectomized rats before mi- 
croalbuminuria was present with the ACE inhibitor, fos- 
inopril, markedly limited the development of progressive 
albuminuria fter 8 months of diabetes, compared with 
control groups receiving either nifedipine or no antihy- 
pertensive agent. The value for UAER in the ACE inhib- 
itor group was 32 mg/day, for the nifedipine group 
136 mg/day and 113 mg/day for the group without anti- 
hypertensive therapy [48]. The positive effect of ACE 
inhibition on the development of microalbuminuria h s 
also been conformed inanother animal study [49]. Based 
on these animal trials it could be the case that patients 
with IDDM may profit from the administration of an 
ACE inhibitor even before microalbuminuria h s devel- 
oped. 
A positive effect of dipyridamole on the UAER of 
patients uffering from diabetes mellitus has been report- 
ed [50]. In 27 patients uffering from NIDDM an in- 
crease in the Ualb/U . . . .  t ratio of 0.80 per month was found 
over an observation period of 10.8 months. After the 
observation period 11 patients with a U,1b/U .... t ratio of 
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> 1.0 were treated with 50 mg d ipyr idamole  three times 
dai ly for 4.2 months.  A decrease in the Ua~ b/U .... t rat io of  
0.36 per month  was found. Four  of  the patients were on 
insulin, the others were taking oral antidiabetics.  An-  
other 15 patients without a pr ior  observat ion per iod and 
a U,~b/U .... t rat io > 1.0 received the same amount  of  
d ipyr idamole  for 9 months,  result ing in a decrease in the 
U,~b/U .... ~ rat io of  0.43 per month.  Unfor tunate ly  the 
authors did not  record the dai ly a lbumin excretion to 
demonstrate  the effect of  d ipyr idamole  on UAER.  Fur -  
thermore,  unt imed urine samples were taken. It  is there- 
fore diff icult to compare the above results with those of  
other study regimens, and further, more standardized 
evaluat ions of  d ipyr idamole  in diabetic nephropathy  are 
needed. 
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